FOOD AND DRUG ADMINISTRATION ISSUES NOTICE: FINANCIAL TRANSPARENCY AND EFFICIENCY OF THE PRESCRIPTION DRUG USER FEE ACT, BIOSIMILAR USER FEE ACT, AND GENERIC DRUG USER FEE AMENDMENTS; PUBLIC MEETING; REQUEST FOR COMMENTS

WASHINGTON, Aug. 21 -- Food and Drug Administration has issued a notice called: Financial Transparency and Efficiency of the Prescription Drug User Fee Act, Biosimilar User Fee Act, and Generic Drug User Fee Amendments; Public Meeting; Request for Comments.

The notice was published in the Federal Register on Aug. 21 by Grace R. Graham, Deputy Commissioner for Policy, Legislation, and International Affairs.

Summary: The Food and Drug Administration (FDA or the Agency) is announcing the following public meeting entitled "Financial Transparency and Efficiency of the Prescription Drug User Fee Act, Biosimilar User Fee Act, and Generic Drug User Fee Amendments." The topic to be discussed is the financial transparency and efficiency of the Pres...